

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Advance health care directives, 405–406
- Aging, cognitive impairments and, 392–395
memory and, 391–392
- Alendronate, in osteoporosis, 470–471
- Alzheimer's Association's 10 Warning Signs, 400–402
- Alzheimer's disease, as cause of dementia, 398–403
criteria for diagnosing, 402
- Amalgam, dental, 320
- Amifostine, 317
- Anabolic agents, in osteoporosis, 473
- Analgesics, 420–421
- Anesthetics, local, 422–423
- Angiotensin-converting enzyme inhibitors, 414–415
- Anti-inflammatory agents, 421
- Antibiotics, 419–420
- Antibodies/infectious diseases, oral-based diagnostic tests for, 454
- Antidepressants, tricyclic, in trigeminal neuropathy, 352
- Antihypertensive agents, 416
- Arthritis, polyjoint, in elderly, 327
in temporomandibular joint, pharmacologic treatment of, 337–338, 339
social and economic impact of, 327–328
- Arthrocentesis-based lavage, in osteoarthritis of temporomandibular joint, 335–336, 339
- Autoimmune diseases, saliva and, 311–314

B

- Biphosphates, in osteoporosis, 470–471, 475
- Blepharospasm, 344
- Bone mineral density, hormone replacement therapy and, 468–469
low femur, prevalence of, 464
measurement of, using dual energy x-ray absorptiometry (DEXA), 465–466
reduced, 463
- Bruxism, 344–345
- Burning mouth symptoms, 354–356
- Burning tongue, 354

C

- Caffeine consumption, and osteoporosis, 468
- Calcitonin, in osteoporosis, 472
- Calcium, intake in aging, 467
supplemental, to prevent bone loss, 469, 470
- Calcium channel blockers, 415
- Cancer, oral, 369
saliva-based diagnostics for, 455
- Capsaicin cream, in osteoarthritis of temporomandibular joint, 334
- Carbamazepine, in trigeminal neuralgia, 350
- Cardiovascular diseases, and periodontitis, in elderly, 287
- Cardiovascular drugs, 414–416
- Care staff, long-term, 380–381
- Caregivers, informal, 379–380
- Caries, alternative management strategies for, 303–304
and restorative considerations, in dry mouth, 319–322

Caries (*continued*)

- coronal, 294–295, 297, 302
- etiology of, 293–294
- flow of saliva and, 309–310
- in older adults, **293–308**, 431–433
- incidence of, 295–296
- management of, 302–303
 - future directions in, 304–305
- oral-based diagnostic tests for, 452–453
- prevalence of, 294–295
 - in nursing home elderly, 295, 296
- prevention of, 299–302
- root surface, 295, 297, 302–303
- significance of, risk factors for, 298–299
 - to health and economics, 296–298
- untreated, in elderly, 367

Cevimeline, 318, 319

Chlorhexidine, for caries control, 301

Cimetidine, 417

Clonazepam, in burning mouth symptoms, 355

Cognitive changes, identification of, in dental office, 390–391
in elderly, recognition of, 395–396

Cognitive function, aging, and ethical decisions, **389–410**

- hints and suggestions for addressing, 406–408
- loss of, with age, 391–392

Cognitive impairment(s), and aging, 392–395
mild, 396–398

Compomers, 321

Corticosteroid injections, in osteoarthritis of temporomandibular joint, 333, 339

D

Decision-making capacity, assessment of, 404–405

Dementia, 392–395
symptoms of, observed by dental team, 403

Dental and medical care, demand for, 449–452
for old-old, 451
for oldest-old, 450–451
for young-old, 451–452

Dental care, versus medical care, subsidized, 366

Dental caries. See *Caries*.

Dental disability, adaptations to cope with, 436–438

Dental disease, educational programs to prevent, 436–438

Dental implants, osteoporosis and, 477–478

Dental office, identification of cognitive changes in, 390–391

Dental use services, 366–367

Dentists, medications prescribed by, 419–423

Diabetes mellitus, and periodontitis, in elderly, 287–288

Digoxin, 416

Diuretics, 415

Drug monitoring, therapeutic, oral diagnostics for, 454–455

Drugs. See *Medications*.

Dry mouth, restorative treatment in, 319–322

Durable power of attorney for health care, 405

Dysesthesia, occlusal, 356–359
explanations for, 357–358
treatment of, 358–359

Dysmorphophobia, 358

Dystonia, 344, 345

E

Edentulousness, in elderly, 282–283

Elderly, at risk for periodontitis and systemic diseases, **279–292**
caries and, 431–433
caring for, effective communication in, 383–388
health care team and, 378–379
interaction with health team members in, **377–388**
cognitive changes in, recognition of, 395–396
definition of, 279
emergency and diagnostic services for, 431
frail, oral health status of, 430–431
gingivitis and periodontal disease in, 434
issues of, underserved in United States, burdens of oral and medical health care, **363–376**

- medication use and prescribing considerations for, **411–427**
 - oral diagnosis for, **445–461**
 - oral hygiene and, 434–435
 - oral implants for, 433–434
 - prevention and treatment strategies for, 431–435
 - prosthodontics for, 433
 - restorative treatment for, 433
 - Elderly Americans, and oral health status, 366–368
 - rationale for targeting, 364–365
 - Endocrine agents, 418–419
 - Estrogen-receptor modulators, selective, in osteoporosis, 471–472
 - Ethical decisions, cognitive function, and aging, **389–410**
 - hints and suggestions for addressing, 406–408
 - Etidronate, in osteoporosis, 471
 - Exercises, in osteoarthritis of temporomandibular joint, 333
- F**
-
- Facial pain, of neurovascular origin, 349
 - of vascular origin, 347–349
 - related to chronic trigeminal neuropathy, 351–353
 - related to muscle pain, 345–347
 - related to postherpetic neuralgia, 353–354
 - related to trigeminal neuralgia, 349–351
 - Fibromyalgia syndrome, 345–346
 - behavioral treatments in, 347
 - medications for, 346
 - Florida Dental Care Study, 370
 - Fluoride, in osteoporosis, 472–473
 - Fluoride dentifrice, to prevent caries, 299–300
 - Fluoride gels, to prevent caries, 300–301
 - Fluoride-releasing restorative materials, 321, 322
 - Fluoride rinses, to prevent caries, 300
 - Fluoride varnishes, to prevent caries, 301
 - Forgetfulness, benign senescent, 396–398
 - Frailty, and long-term care recipients, 430

G

-
- Gastrointestinal agents, 417
 - Geriatric populations. See *Elderly*.
 - Giant cell arteritis, 347–348
 - Gingiva, recession of, 281–282
 - Gingivitis, in older adults, 434
 - Glass ionomers, conventional, 320
 - resin-modified, 320, 321
 - Glossopyrosis, 354

H

-
- Health care, disparities in, history of, 365–366
 - poor access to, risk factors for, 363
 - Health care information, essential, 381–383
 - Health care proxies, 405
 - Health record, for older adults, basic elements of, 381–382
 - decisional support and advanced directives of, 383
 - functional assessment in, 382–383
 - social history in, 382
 - Histamine-2 receptor antagonists, 417
 - Hormone replacement therapy, bone mineral density and, 468–469
 - Hyaluronic acid injections, in osteoarthritis of temporomandibular joint, 334
 - Hypertension, salivary hypofunction, 315

I

-
- Ibandronate, in osteoporosis, 471
 - Immune system, periodontitis, in elderly, 284
 - Informed consent, cognitive impairment and, 403–404
 - Informed decisions, ability to make, factors compromising, 404

L

-
- Letters, consultative, for care of elderly patients, 385, 386, 387
 - Levothyroxine, 419
 - Lidocaine patch, transdermal, in osteoarthritis of temporomandibular joint, 335
 - Life expectancy, 429–430

- Lifespan developmental issues, in frail older adults, 448–449
 - in functionally dependent older adults, 449
 - in functionally independent older adults, 448
 - in oral diagnostics, 447–449
- Living wills, 405, 406
- Long-term care patients, elderly, caring for, future trends in, 438–439
 - oral-health-related concerns in, **429–443**
 - quality of life in, oral health and, 437–438
 - frailty and, 430
- Long-term care staff, 380–381

M

- Medicaid, 366
- Medical care, versus dental care, subsidized, 366
- Medications, frequently prescribed for older adults, 414–416
 - dental management considerations and, 415
 - oral effects of, for treatment of osteoporosis, 474
 - prescribed by dentists, 419–423
 - problematic or potentially inappropriate, for older adults, 414
 - problems related to, avoidance of, 423–424
 - factors contributing to, 413
 - polymedicine and, 412–413
 - salivary hypofunction and, 311
 - use of, and prescribing considerations for, in elderly, **411–427**
 - by older adults, 411–412
- Memory, and aging, 391–392
- Mouth, dry, restorative treatment in, 319–322
- Muscle pain, facial pain related to, 345–347
- Myalgia, localized, 345
- Myofascial pain, 345
 - behavioral treatments in, 347
 - medications for, 346

N

- Nonsteroidal anti-inflammatory drugs, 416–417, 422

O

- Older adults. See *Elderly*.
- Omeprazole, 418
- Oral cancer. See *Cancer, oral*.
- Oral cavity, fluids of, for oral diagnostics, 446
- Oral diagnosis, and blood testing, compared, 445–447
 - approaches to, 445
 - benefits of, 445
 - for geriatric populations, **445–461**
- Oral diagnostics, future possibilities for, 455–457
 - lifespan developmental issues in, 447–449
 - specific applications of, 452–455
- Oral health, osteoporosis and, 477–478
- Oral health professionals, in recognition of cognitive changes, 395–396
- Oral-health-related concerns, in caring for elderly long-term care patients, **429–443**
- Oral hygiene, elderly and, 434–435
- Oral implants, for older adults, 433–434
- Oral motor disorders, facial pain in, 344–345
 - management of, 345
- Orofacial pain, and sensory disorders, in elderly, **343–362**
 - prevalence of, 343
 - types of, 343
- Osteoarthritis, polyjoint, and temporomandibular joint, in elderly, 336–337
 - in elderly, 327
- Osteoporosis, and oral health, 476–477
 - implications for dentistry, **463–484**
 - and periodontitis, in elderly, 288–289
 - dental implants and, 477–478
 - future study directions in, 478
 - in men, 474–476
 - incidence of, 463–464
 - morbidity and mortality associated with, 464–465
 - nature of, 465
 - pharmacotherapies for, 469–474
 - prevention of, 467–468
 - actions for dentists for, 478–480

risk factors for, 466
 risk of, screening for, 466–467
 treatment of, oral effects of, 474

P

Pamidronate, in osteoporosis, 471
 Parathyroid hormone, in osteoporosis, 473
 Periodontal disease, 368
 in older adults, 434
 oral-based diagnostic tests for, 453–454
 Periodontal medicine, 280
 Periodontitis, aggressive, 280
 and systemic diseases, elderly at risk for, **279–292**
 chronic, 280
 decrease in prevalence of, 282
 immune system and, in elderly, 284
 microbiologic etiology of, in elderly, 284
 prevalence of, and tooth loss in elderly, 281–284
 studies of, 282
 risk profile for, 289–290
 self-perception, quality of life and, in elderly, 285
 severity of, factors defining, 283
 smoking and, in elderly, 286–287
 socioeconomic status and, 285–286
 systemic diseases and, 287–289
 Periodontium, age-related alterations in, 283
 Pilocarpine, 318–319
 Postherpetic neuralgia, facial pain related to, 353–354
 Power of attorney, 405
 Prosthodontics, for older adults, 433
 Protein-calorie malnutrition, 468
 Proton pump inhibitors, 417
 Psychotropic agents, 418

Q

Quality of life and longevity, impact on, 371

R

Radiation therapy, salivary hypofunction following, 314–315
 Raloxifene, in osteoporosis, 472

Resins, composite, 320, 321
 polyacid-modified, 320
 Restorative materials, 320
 direct, in reduced salivary flow, 321–322
 fluoride-releasing, 321, 322
 Restorative treatment, for older adults, 433
 in dry mouth, 319–322
 Rheumatic arthritis, and temporomandibular joint, in elderly, 337
 Risedronate, in osteoporosis, 471

S

Saliva, autoimmune diseases and, 311–314
 flow of, and caries, 309–310
 functions of, 309
 Salivary glands, diseases of, treatment of, 315
 stimulation of, systemic, 318–319
 with local or topical regimens, 318
 Salivary hypofunction, and xerostomia, diagnosis and treatment of, **309–326**
 direct restorative materials in, 321–322
 following radiation therapy, 314–315
 in elderly, xerostomia and, 310, 312–313
 in hypertension, 315
 medications and, 311
 prevention of, 315–317
 treatment of, 316–318
 Sedatives, 421–422
 Sensory disorders, and orofacial pain, in elderly, **343–362**
 Sjögren's syndrome, 311–314
 Smoking, and periodontitis, in elderly, 286–287
 as risk factor for osteoporosis, 468
 Socioeconomic disparities, health outcomes and, 369–370
 Statins, in osteoporosis, 473
 Stomatopyrosis, 354–356
 Sulfonyleureas, 418
 Systemic diseases, periodontitis and, elderly at risk for, **279–292**
 Tamoxifen, in osteoporosis, 471

Temporal arteritis, 347, 348–349

Temporomandibular joint, anatomy and physiology of, normal and age-related changes in, 328–330
and polyjoint osteoarthritis, in elderly, 336–337
derangement, osteoarthritis, and rheumatoid arthritis of, **327–342**
local disk dysfunction, in elderly, 330–331
localized osteoarthritis of, in elderly, 331–332
treatment of, 332–336
polyjoint arthritis in, pharmacologic treatment of, 337–338, 339
rheumatic arthritis and, in elderly, 337
wear-and-tear-related problems of, with aging, 329–330

Thiazides, 415

Tibolone, in osteoporosis, 472

Tooth loss, impact of, in elderly, 282
reasons for, 283

Torticollis, 344

Triamcinelone, in osteoarthritis of temporomandibular joint, 333

Tricyclic antidepressants, in trigeminal neuropathy, 352

Trigeminal neuralgia, facial pain related to, 349–351
International Headache Society criteria for, 350

Trigeminal neuropathy, chronic, diagnosis of, 351–352
clinical features of, 352
treatment of, 352–353

Trihexyphenidyl, 345

V

Vascular inflammatory syndrome, chronic, 347–349

Vitamin D, intake in aging, 467
recommended intake of, 469

W

Warfarin, 416, 417

X

X-ray absorptiometry, dual energy (DEXA), for bone mineral density measurement, 465–466

Xerostomia, prevalence of, decreased salivary flow, in elderly, 310, 312–313
restorative considerations in, 319–322
salivary hypofunction and, diagnosis and treatment of, **309–326**

Xylitol, for caries prevention, 301–302

Z

Zoledronate, in osteoporosis, 471